drugset
drugset / Trial / NCT05840094

Multimodalitic Imaging in the N-stage of Lung Cancer

NCT05840094 ↗

Unknown 100 enrolled Peking University First Hospital
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

This study aims to evaluate the diagnostic efficacy and differences between 18F-FDG PET/CT and MR STIR sequences combined with EBUS-TBNA, 18F-FDG PET/CT combined with EBUS-TBNA, and MR STIR sequences combined with EBUS-TBNA - three types of multimodal imaging for assessing NSCLC N-stage, in order to select the best assessment protocol to guide treatment decisions and prognostic assessments.

Timeline

Start
2023-05-01
Primary completion
2025-05-01
Completion
2025-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FDG Diagnostic / imaging agent 3.7 mbq/kg Intravenous

Indications

lung neoplasm